The implications of drug resistance for strategies of combination antiviral chemotherapy

Antiviral Research

Volumn 29, Issue 1, 1996, Pages 31-33

  Richman, Douglas D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiviral chemotherapy; Drug resistance; HIV

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR; LAMIVUDINE; NEVIRAPINE;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; DRUG MECHANISM; DRUG RESISTANCE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HIV; HUMANS; MUTATION;

EID: 0029918470     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/0166-3542(95)00911-6     Document Type: Article

References (17)

1. Chow, Y.-K., Hirsch, M.S., Merrill, D.P., Bechtel, L.J., Eron, J.J., Kaplan, J.C. and D'Aquila, R.T. (1993) Replication incompatible and replication compromising combinations of HIV-1 RT drug resistance mutations. Nature 361, 650-654.
2. Coen, D.M. (1991) The implications of resistance to antiviral agents for herpesvirus drug targets and drug therapy. Antiviral Res. 15, 287-300.
3. Erickson, J.W. (1995) Structural mechanisms of drug resistance to HIV-1 protease inhibitors: therapeutic implications. Nature Structural Biol. 2, 523-529.
4. Havlir, D., Cheeseman, S.H., McLaughlin, M., Murphy, R., Erice, A., Spector, S.A., Greenough, T.C., Sullivan, J.L., Hall, D., Myers, M., Lamson, M. and Richman, D.D. (1995a) High dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J. Infect. Dis. 171, 537-545.
5. Havlir, D., Eastman, S. and Richman, D.D. (1995b) HIV-1 kinetics: rates of production and clearance of viral populations in asymptomatic patients treated with nevirapine. First National Conference on Human Retroviruses and Related Infections, Washington, D. C., January 1996 (Abstract).
6. Hayden, F.G. and Couch, R.B. (1992) Clinical and epidemiological importance of influenza A viruses resistant to amantadine and rimantadine. Rev. Med. Virol. 2, 89-96.
7. 2-symmetric protease inhibitor. J. Virol. 68, 2016-2020.
8. Kozal, M.J., Shah, N., Yang, R., Shen, N., Fucini, R., Merigan, T.C., Richman, D.D., Chee, M.S. and Gingeras, T.R. (1995) Natural polymorphism of HIV-1 clade B protease gene and the implication for therapy. 4th International HIV Drug Resistance Workshop, Sardinia, Italy. June 9-11. (Abstract).
9. Monto, A.S. and Arden, N.H. (1992) Implications of viral resistance to amantadine in control of influenza A. Clin. Infect. Dis. 15, 362-367.
10. Nájera, I., Richman, D.D., Olivares, I., Rojas, J.M., Peinado, M.A., Perucho, M., Nájera, R. and López-Galíndez, C. (1994) Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Res. Hum. Retroviruses 10, 1479-1488.
11. Nájera, I., Holguín, A., Quiñones-Mateu, M.E., Muñoz-Fernández, M.A., Nájera, R., López-Galíndez, C. and Domingo, E. (1995) pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J. Virol. 69, 23-31.
12. Richman, D.D. (1994a) Drug resistance in viruses. Trends Microbiol. 2, 401-407.
13. Richman, D.D. (1994b) Resistance, drug failure, and disease progression. AIDS Res. Hum. Retroviruses 10, 901-905.
14. Richman, D.D. (1994c) Viral resistance to antiretroviral therapy. In: S. Broder, T.C. Merigan and D. Bolognesi (Eds), Textbook of AIDS Medicine, pp. 795-805. Baltimore: Williams and Wilkins.
15. Richman, D.D. (1995) Drug resistance in relation to pathogenesis. AIDS 1995 (9 (Supppl. A): S49-S53.
16. Schuurman, R., Nijhuis, M., van Leeuwen, R., Schipper, P., Collis, P., Danner, S., Mulder, J., Loveday, C., Christopherson, C., Kwok, S., Sninsky, J. and Boucher, C.A.B. (1995) Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine. J. Infect. Dis. 171, 1431-1437.
17. Tisdale, M., Kemp, S.D., Parry, N.R. and Larder, B.A. (1993) Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90, 5653-5656.